Company selection criteria. Quality, time & cost. Hunger ... USA - Legal, IP, BD, finance, preclinical. Outcome: From target to animal studies in 6 months! ...
... was most recently Senior VP of drug discovery and licensing at Versicor (re-named Vicuron) ... list at the website: http://www.BioE2E.org. Volunteer list: ...
MRSA is seldom eradicated quickly, and improvements in activity could yield shorter T-erad ... Accept only MRSA positive patients on vanco for at least 5 days ...
Lilly Pharmaceuticals. Merck Research Laboratories. Ortho-Biotech. Pfizer, Inc. ... Will use echinocandin to refer to both echinocandins and pneumocandins ...
University of North Texas Health Science Center in Fort Worth. Stevan Cordas DO MPH ... symptoms rhinitis, sinusitis, asthma, SOB, chest discomfort, epistaxis. ...
Actif sur levures et filaments = Candida sp., Candida r sistant au ... Peu actif sur les agents de mucormycoses. Denning et al: invasive aspergillosis: clinical ...
Neutropenic guinea pig model. Vori reduced kidney CFU/g better than AmB or Flu ... Neutropenic guinea pig, C. krusei. Vori MIC 0.5, Flu MIC 32 (M27-A, 48h) ...
Medarex and ... The Deal. Generates fully-human antibodies in mice ... Many investors give no credit for a Medarex deal. Conclusions. 22. Conclusions ...